Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

merck-keytruda

Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund

August 8, 2019
Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …

News
nice_new_london_office_internal_2_8

NICE reject Clovis Oncology’s ovarian cancer drug Rubraca

August 6, 2019
Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma

Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib). On 6 August, NICE issued …

News

Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease

August 1, 2019
Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 26, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten

At the end of a week that could certainly be called “eventful” here in the UK – one that saw …

News

AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers

July 26, 2019
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma

NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …

News
nice_new_london_office_internal_2_8

NICE to review its decision making processes

July 22, 2019
Sales and Marketing Cost, NHS, NICE, UK, britain, pharma

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, …

News

NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer

July 17, 2019
Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma

Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

July 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HPV, NHS, NICE, Novartis, Pfizer, Trump, pharma, vaccines

This week’s most popular story covered news of Trump’s claims that he will introduce an executive order to ensure the …

News

NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

July 5, 2019
Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …

News

Alimera Sciences secures NICE recommendation for uveitis eye implant

June 21, 2019
Medical Communications, Sales and Marketing Alimera Sciences, NICE, UK, pharma, uveitis

Britain’s cost effectiveness body NICE has recommended the use of the fluocinolone acetonide implant, a new treatment option for patients …

News

NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population

June 19, 2019
Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma

Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …

News
nice_new_london_office_internal_2_8

RCP calls on NICE to update guidelines on coming off antidepressants

May 31, 2019
Medical Communications Guidelines, NICE, RCP, antidepressants, health, pharma

Guidance for patients on coming off antidepressants needs to be updated, according to the Royal College of Psychiatrists (RCP). Current …

News
merckwindow_web

NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant

May 31, 2019
Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma

MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …

News

Akcea’s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR

May 23, 2019
Sales and Marketing Akcea Therapeutics, NHS, NICE, Tegsedi, UK, pharma

Akcea Therapeutics’ Tegsedi (inotersen) has received recommendation from NICE, the company has revealed, meaning the therapy will now be made …

News
celgene_building

NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma

May 20, 2019
Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma

Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026